Market Overview

Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock

Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock
The Alzheimer's Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease
18 Stocks Moving In Friday's Pre-Market Session
AC Immune reports FY results (Seeking Alpha)
Related AGN
Barron's Picks And Pans: Allergan, Broadcom, Gap And More
Allergan Considering All Strategic Options 'With A Sense Of Urgency'
Paratek: A Review Of Progress And Preview Of 2018 (Seeking Alpha)

After Eli Lilly and Co (NYSE: LLY) earlier announce the failure of its Alzeheimer’s candidate solanezumab, the entire Alzheimer's sector could feel the aftershocks. While some of the players have since recovered from early morning drops, a few are still in the red in early Wednesday afternoon.

Alzheimer's Treatment Stocks

Below are the players within the sector, and their subsequent stock movements at time of writing:

  • AC Immune Ltd (NASDAQ: ACIU): Down 16.06 percent at $11.50.
  • Alkermes Plc (NASDAQ: ALKS): Up 0.69 percent at $58.74.
  • Anavex Life Sciences Corp. (NASDAQ: AVXL): Up 6.76 percent at $3.63.
  • Biogen Inc (NASDAQ: BIIB): Down 3.94 percent at $305.59.
  • Eli Lilly and Co: Down 10.76 percent at $67.82.
  • Neuralstem, Inc. (NASDAQ: CUR): Up 3.81 percent at $0.270.
  • Novartis AG (ADR) (NYSE: NVS): Up 0.98 percent at $68.76.
  • Roche Holding Ltd. (ADR) (OTC: RHHBY): Down 1.3 percent at $27.40.

Posted-In: alzheimer's solanezumabBiotech News Movers & Shakers Movers Trading Ideas General Best of Benzinga


Related Articles (AGN + ACIU)

View Comments and Join the Discussion!